Abstract
Restriction of dietary phosphate intake is beneficial in preventing the development of secondary hyperparathyroidism and bone disease in experimental renal failure in the dog (l–3). If associated with vitamin D administration, this dietary regimen can prevent both pathologic bone resorption and osteomalacia in the same experimental model (3). In rats with surgically-induced renal failure, the administration of phosphate-deficient diets (0.03% phosphate) is followed by anorexia, hypophosphatemia, growth arrest, stunting, and severe rickets (4,5). On the other hand, growth failure is also commonly observed when the same animals are given high-phosphate diets (1.58 % phosphate) (6).
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Preview
Unable to display preview. Download preview PDF.
References
SLATOPOLSKY E., CAGLAR S., PENNELL J.P., TAGGART D.D., CANTERBURY J. M., REISS E., BRICKER N.S.: On the pathogenesis of hyperparathyroidism in chronic experimental renal insufficiency in the dog. J.Clin.Invest. 50, 422–499, 1971.
SLATOPOLSKY E., CAGLAR S., GRADOWSKA L., CANTERBURY J., REISS E., BRICKER N.S.: On the prevention of secondary hyperparathyroidism in experimental chronic renal disease using “proportional reduction” of dietary phosphorus intake. Kidney Intern. 2, 147151, 1972.
RUTHERFORD W.E., BORDIER P., MARIE P., HRUSKA K., HARTER H., GREENWALT A., BLONDIN J., HADDAD J., BRICKER N., SLATOPOLSKY E.: Phosphate control and 25-hydroxycholecalciferol administration in preventing experimental renal osteodystrophy in the dog. J.Clin. Invest. 60, 332–341, 1977.
SALUSKY I., KLEINKNECHT C., BROYER M., GUBLER M.-C.: Prolonged renal survival and stunting with protein-deficient diets in experimental uremia. J.Lab.Clin.Med. 97, 21–30, 1981.
LAOUARI D., KLEINKNECHT C., COURNOT-WITMER G., HABIB R., BROYER M.: Importance of anorexia in the preservation of renal function due to deficient phosphorus diets. Third Intern.Congr.Nutrition and Metabolism in Renal Disease,Abstract Book,n. 89, 1982.
KLEINKNECHT C., SALUSKY I., BROYER M., GUBLER M.-C.: Effect of various protein diets on growth, renal function, and survival of uremic rats. Kidney Intern. 15, 534–541, 1979.
FELETTI C., DOCCI D., CAPELLI M., BONOMINI V.: Pathophysiology of endogenous calcitonin in chronic uremia. Min.Electrol.Metab. 6, 174–181, 1981.
HEYNEN G., KANIS J.A., OLIVER D., LEDINGHAM J.G.G., RUSSELL R.G.G.: Evidence that endogenous calcitonin protects against renal bone disease. Lancet 2, 1322–1326, 1976.
KANIS J.A., EARNSSHAW M., HEYNEN J., RUSSELL R.G.G., WOODS C.G.:The possible role of calcitonin deficiency in the development of bone disease due to chronic renal failure. Calcif.Tissue Res. 22, 147–153, 1977.
HABENER F., SCHILLER A.L.: Pathogenesis of renal osteodystrophy: a role for calcitonin ? New Engl.J.Med. 296, 1112–1113, 1977.
FELETTI C., BONOMINI V.: Effect of calcitonin on bone lesions in chronic dialysis patients. Nephron 24, 85–88, 1979.
FARRINGTON K., VARGHESE Z., MOORHEAD J.F.: Human calcitonin in the treatment of renal osteodystrophy. J.Labor.Clin.Med. 96, 299–306, 1980.
CUNDY T., KANIS J.A., HEYNEN G., PATON S., EARNSHAW M., WOODS C.G.: Deterioration of renal bone disease in patients treated with salmon calcitonin. Clin.Endocrinol. 16, 29–37, 1982.
Author information
Authors and Affiliations
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 1984 Plenum Press, New York
About this chapter
Cite this chapter
D’Angelo, A. et al. (1984). Phosphate-Restricted Diets versus Calcitonin in the Prevention of Osteodystrophy in Experimental Renal Disease. In: Massry, S.G., Maschio, G., Ritz, E. (eds) Phosphate and Mineral Metabolism. Advances in Experimental Medicine and Biology, vol 178. Springer, Boston, MA. https://doi.org/10.1007/978-1-4684-4808-5_32
Download citation
DOI: https://doi.org/10.1007/978-1-4684-4808-5_32
Publisher Name: Springer, Boston, MA
Print ISBN: 978-1-4684-4810-8
Online ISBN: 978-1-4684-4808-5
eBook Packages: Springer Book Archive